Lyka Labs Ltd.
Snapshot View

61.45 +0.55 ▲0.9%

23 July 2021, 04:00:00 P.M.
Volume: 18,383

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.lykalabs.com
Financial Indicators
Market Cap 178.60 Cr.
Earnings per share (EPS) -4.03 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share -8.52 Trailing Twelve Months Ending 2021-03
Price to Book Value -7.31 Calculated using Price: 62.25
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 2.87 Cr. 28,690,000 Shares
FaceValue 10
Company Profile

Lyka Labs Ltd was incorporated on December 29, 1976 as a private limited company and converted into a public limited company on  December 19, 1985.

The company is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.

Lyka Labs is committed to creating a better tomorrow for India. Maintaining a core competency in Lyophilization, allows Lyka Labs to supply Freeze Dried Drugs in sufficient quantities with the right quality. Lyka strives to manage this business in an ethical and transparent manner.

Lyka has 2 manufacturing facilities in Ankleshwar and Tarapur. There is also an R & D facility based in Chakala, Mumbai, and a corporate head office based in Andheri, Mumbai.

Plant located at Ankleshwar, Gujarat is one of the largest chemical Industrial estates in Asia. Located approx. 10 kms from the city of Bharuch, Gujarat. Ankleshwar is well connected and can be reached by road, rail or air from Mumbai, or by road and rail from Vadodara, or Ahmedabad.

Tarapur Plant is located in the MIDC Industrial Estate in Tarapur, District Thane, Maharashtra. Located approximately 80 kms from Mumbai City, and well connected by rail and road to Mumbai. 

Different business lines of the company:

  • Contract Manufacturing - Lyka undertakes manufacturing activities for a number of different companies on a Principal to Principal Basis. In most cases Lyka would undertake the entire manufacturing process, from sourcing of raw materials to manufacture to packaging, although Lyka also offers job work services where the raw materials are sourced by the client company. Their manufacturing processes are in line with world over best practices, as demonstrated by the ISO 9001:2002 Certification
  • Hospital Division - LYKA has forayed into marketing of products into hospitals/ institutions. To begin with, it has introduced a range of anti-infectives, which include systemic antimalarial, antifungal and antibacterials for serious infections. Apart from this, it has also introduced anesthetics, anti-ulcerants and steroid in parenteral dosage forms. On the anvil is the expansion of the range of the products in the above therapeutic segments as well as in the new therapeutic segments. The company also has plan to introduce products in solid dosage forms for hospitals / institutions.
  • Lyka Animal Health Care - Lyka Animal Healthcare Division within a short period has made strong presence in Indian Veterinary market with their quality innovative products. The animal healthcare division is managed and headed by veterinary professional with strong and dedicated team of field and in-house persons.
  • Generics - When generic products become available, the market competition often leads to substantially lower prices for both the original brand name product and the generic forms. Lyka markets branded generic products in the form of: -Tablets -Capsules -Ointments -Syrups Dry Powder and Liquids
  • Lyka BDR- Lyka manufactures and sells products to its Joint Venture company Lyka BDR. Lyka BDR is the largest seller of human and veterinary products in Sudan

Product range of the company includes:

  • Ampholyn Inj.  
  • Hydrolin Inj.   
  • Lyom Inj.   
  • Lypan Inj.   
  • Lypitaz Inj. 2.25g   
  • Lypitaz Inj. 4.5g   
  • Lyrab Inj.   
  • Lysunate Inj.  
  • Lysunate Tabs  
  • Lyvec Inj.   
  • Merojet Inj. 500mg   
  • Merojet Inj.1000mg   
  • Stropaz Inj.   
  • Thiolyn Inj. 500mg  
  • Thiolyn Inj.1000mg   
  • Vancolym Inj.   
  • Xolycef - SB Inj.   
  • Xolycef - TZ Inj.   
  • Xolycef Inj. 1000mg 
  • Zimtaz Inj. 

Achievements/ recognition:

  • ISO 9001:2000 certified
  • Recognized as in-house R&D Centre by Government of India, Ministry of Science & Technology, Department of Scientific and Industrial Research.
  • In 2011 the company has been conferred Certificate of Appreciation Patent Award by Pharmaceuticals Export Promotion Council.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.90%
1 Week
+0.16%
1 Month
+7.06%
3 Month
+89.66%
6 Month
+107.95%
1 Year
+248.16%
2 Year
+204.21%
5 Year
-15.01%
9 years 2012-03 2013-03 2014-06 2015-06 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -13.12 0.73 -11.06 -13.05 11.74 -18.27 -46.30 -14.20 -448.65
Return on Capital Employed (%) 12.56 10.68 11.93 11.73 12.41 6.66 -6.52 -5.50 -31.39
Return on Assets (%) -2.51 0.14 -1.72 -1.55 1.58 -2.70 -8.02 -2.97 -32.08

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 74 67 53 43 45 38 49 43 -14
Non Curr. Liab. 74 72 65 37 29 39 5 72 137
Curr. Liab. 132 147 208 195 163 165 167 85 66
Minority Int. 2 3 3 4 4 7 3 3 -1
Equity & Liab. 283 289 329 279 241 249 225 203 188
Non Curr. Assets 168 162 211 177 159 186 176 168 152
Curr. Assets 115 127 118 102 82 63 49 35 36
Misc. Exp. not W/O
Total Assets 283 289 329 279 241 249 225 203 188

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 170 127 119 166 130 110 60 71 61
Other Income 4 3 5 2 2 2 2 2 3
Total Income 174 130 124 169 132 112 62 73 65
Total Expenditure -155 -106 -110 -138 -110 -87 -63 -73 -65
PBIDT 19 25 14 31 22 25 -1 0 -1
Interest -30 -21 -29 -26 -16 -19 -10 -7 -20
Depreciation -9 -12 -9 -11 -9 -10 -11 -7 -8
Taxation -1 -1 0 2 1 9 -1
Exceptional Items 12 8 19 2 7 -4 2 -1 -33
PAT -8 0 -5 -5 4 -7 -19 -6 -63

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 1 11 89 27 12 31 11 27 5
Cash Fr. Inv. 12 5 -57 29 17 -13 -3 -4 0
Cash Fr. Finan. -16 -13 -26 -60 -30 -19 -10 -23 3
Net Change -3 3 6 -4 -1 0 -3 -1 8
Cash & Cash Eqvt 2 5 11 7 6 5 2 2 10

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 18.31 19.88 19.88 19.88 19.88 19.88 19.88 19.88 19.88
Public 81.69 80.12 80.12 80.12 80.12 80.12 80.12 80.12 80.12
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 31.49 28.46 25.83 26.76 26.76 26.76 26.76 26.76 26.76

Announcements View Details

Tue, 20 Jul 2021
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on July 20 2021 for Narendra Ishwarlal Gandhi HUF
Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Lyka Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Tue, 13 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
1010
Name of the Signatory :- Piyush G Hindia
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Fri, 23 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%